{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T10:50:54Z","timestamp":1785408654348,"version":"3.56.0"},"reference-count":57,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP26am0521010"],"award-info":[{"award-number":["JP26am0521010"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP26ama121008"],"award-info":[{"award-number":["JP26ama121008"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25ama221153"],"award-info":[{"award-number":["JP25ama221153"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"crossref","award":["JP25ama221339"],"award-info":[{"award-number":["JP25ama221339"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"award":["JP26am0521010"],"award-info":[{"award-number":["JP26am0521010"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP26ama121008"],"award-info":[{"award-number":["JP26ama121008"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP25ama221153"],"award-info":[{"award-number":["JP25ama221153"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"award":["JP25ama221339"],"award-info":[{"award-number":["JP25ama221339"]}],"id":[{"id":"https:\/\/ror.org\/004rtk039","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["25K10553"],"award-info":[{"award-number":["25K10553"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["26K02289"],"award-info":[{"award-number":["26K02289"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibodies"],"abstract":"<jats:p>Background\/Objectives: Cadherin-17 (CDH17, LI-cadherin) is a non-classical cadherin with an atypical structure and unique functions. CDH17 expression is restricted to normal intestinal epithelium. Furthermore, CDH17 functions as an oncoprotein that promotes tumor migration and invasion in colorectal, gastric, and pancreatic cancers. Therefore, CDH17 is an important diagnostic marker and therapeutic target. The CDH17-directed strategies, including monoclonal antibodies (mAbs), bispecific Abs, antibody\u2013drug conjugates (ADCs), and chimeric antigen receptor (CAR) T cells, have been evaluated in preclinical and clinical studies. Therefore, developing mAbs that specifically recognize cell surface-expressing CDH17 is essential for advancing both tumor diagnosis and therapy. Methods: Anti-human CDH17 mAbs (named Ca17Mabs) were developed by immunizing a mouse with CDH17-overexpressed cells and a high-throughput screening using flow cytometry. Results: Among Ca17Mabs, a clone, Ca17Mab-5 (IgG1, \u03ba) specifically recognized CDH17-overexpressed Chinese hamster ovary-K1 (CHO\/CDH17) cells with no detectable cross-reactivity to 21 other CDHs by flow cytometry. Ca17Mab-5 also detected endogenous CDH17 in human colorectal cancer cell lines, COLO201 and COLO205. The apparent dissociation constant (KD) values of Ca17Mab-5 for CHO\/CDH17 and COLO205 were estimated as 1.5 \u00d7 10\u22128 M and 1.3 \u00d7 10\u22128 M, respectively. Furthermore, Ca17Mab-5 detected endogenous CDH17 by Western blotting. In immunohistochemistry, Ca17Mab-5 exhibited clear membranous staining in normal colon epithelium, colorectal, gastric, and pancreatic cancers. Conclusions: Ca17Mab-5 is a versatile tool for detecting CDH17 and has potential for tumor diagnosis.<\/jats:p>","DOI":"10.3390\/antib15040059","type":"journal-article","created":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T11:43:34Z","timestamp":1783683814000},"page":"59","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Novel Anti-Cadherin-17 Monoclonal Antibody, Ca17Mab-5, for Multiple Applications"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-2286-3488","authenticated-orcid":false,"given":"Reina","family":"Ito","sequence":"first","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5132","authenticated-orcid":false,"given":"Hiroyuki","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutake","family":"Yagi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0652-7041","authenticated-orcid":false,"given":"Akira","family":"Ohkoshi","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Katori","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, 1-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4158-9208","authenticated-orcid":false,"given":"Mika K.","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5385-8201","authenticated-orcid":false,"given":"Yukinari","family":"Kato","sequence":"additional","affiliation":[{"name":"Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1038\/nrc3647","article-title":"Beyond E-cadherin: Roles of other cadherin superfamily members in cancer","volume":"14","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1083\/jcb.201008173","article-title":"Evolution: Structural and functional diversity of cadherin at the adherens junction","volume":"193","author":"Oda","year":"2011","journal-title":"J. Cell Biol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.semcdb.2022.11.004","article-title":"Cell sorting in vitro and in vivo: How are cadherins involved?","volume":"147","author":"Takeichi","year":"2023","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/nrm3802","article-title":"Dynamic contacts: Rearranging adherens junctions to drive epithelial remodelling","volume":"15","author":"Takeichi","year":"2014","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrm3431","article-title":"A bigger picture: Classical cadherins and the dynamic actin cytoskeleton","volume":"13","author":"Ratheesh","year":"2012","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1016\/j.jmb.2007.04.062","article-title":"Intestinal LI-cadherin acts as a Ca2+-dependent adhesion switch","volume":"370","author":"Wendeler","year":"2007","journal-title":"J. Mol. Biol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1083\/jcb.136.5.1109","article-title":"LI-cadherin-mediated cell-cell adhesion does not require cytoplasmic interactions","volume":"136","author":"Kreft","year":"1997","journal-title":"J. Cell Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1083\/jcb.125.6.1353","article-title":"Liver-intestine cadherin: Molecular cloning and characterization of a novel Ca(2+)-dependent cell adhesion molecule expressed in liver and intestine","volume":"125","author":"Berndorff","year":"1994","journal-title":"J. Cell Biol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/PAP.0000000000000008","article-title":"Cadherin 17 is a novel diagnostic marker for adenocarcinomas of the digestive system","volume":"21","year":"2014","journal-title":"Adv. Anat. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/path.5138","article-title":"Deletion of cadherin-17 enhances intestinal permeability and susceptibility to intestinal tumour formation","volume":"246","author":"Chang","year":"2018","journal-title":"J. Pathol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/modpathol.2008.107","article-title":"Cadherin-17 is a useful diagnostic marker for adenocarcinomas of the digestive system","volume":"21","author":"Su","year":"2008","journal-title":"Mod. Pathol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1038\/onc.2013.117","article-title":"Cadherin-17 interacts with \u03b12\u03b21 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis","volume":"33","author":"Barderas","year":"2014","journal-title":"Oncogene"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Tha Shrestha, B., Feng, Y., Lad, A., Bates, A., Chen, J., Brown, K., Zeng, F., and Wang, N. (2025). The Role of Cadherin 17 (CDH17) in Cancer Progression via Wnt\/\u03b2-Catenin Signalling Pathway: A Systematic Review and Meta-Analysis. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26209838"},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Casal, J.I., and Bartolom\u00e9, R.A. (2019). Beyond N-Cadherin, Relevance of Cadherins 5, 6 and 17 in Cancer Progression and Metastasis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20133373"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13046-024-02956-6","article-title":"A complex of cadherin 17 with desmocollin 1 and p120-catenin regulates colorectal cancer migration and invasion according to the cell phenotype","volume":"43","author":"Robles","year":"2024","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"34801","DOI":"10.1074\/jbc.M114.600502","article-title":"An RGD motif present in cadherin 17 induces integrin activation and tumor growth","volume":"289","author":"Gomez","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/s41419-025-07811-w","article-title":"Loss of cadherin 17 downregulates LGR5 expression, stem cell properties and drug resistance in metastatic colorectal cancer cells","volume":"16","author":"Robles","year":"2025","journal-title":"Cell Death Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Katoh, M., Loriot, Y., Nakayama, I., Hamada, A., Shitara, K., and Katoh, M. (2025). Antibody-drug conjugates targeting the cadherin, claudin and nectin families of adhesion molecules. Front. Mol. Med., 5.","DOI":"10.3389\/fmmed.2025.1661016"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1158\/1078-0432.CCR-17-2823","article-title":"Targeting CDH17 in Cancer: When Blocking the Ligand Beats Blocking the Receptor?","volume":"24","author":"Marshall","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1158\/1538-7445.AM2024-1900","article-title":"Abstract 1900: TORL-3-600, a novel antibody drug conjugate directed against cadherin 17 (CDH17), has preclinical efficacy in colorectal, gastric, and pancreatic cancer","volume":"84","author":"McDermott","year":"2024","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"TPS3161","DOI":"10.1200\/JCO.2025.43.16_suppl.TPS3161","article-title":"A phase 1, first-in-human study of AMT-676, an anti-CDH17 antibody-drug conjugate, in patients with advanced gastrointestinal tumors","volume":"43","author":"Lemech","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2940","DOI":"10.1158\/1538-7445.AM2025-2940","article-title":"Abstract 2940: Preclinical development of a next generation antibody drug conjugate (ADC) targeting CDH17 for treatment of solid tumors","volume":"85","author":"Lian","year":"2025","journal-title":"Cancer Res."},{"key":"ref_23","first-page":"102401","article-title":"Development of novel anti-CDH1\/E-cadherin monoclonal antibodies for versatile applications","volume":"45","author":"Ubukata","year":"2026","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_24","first-page":"34","article-title":"A Novel Anti-CDH5\/VE-Cadherin Monoclonal Antibody (Ca(5)Mab-8) for Flow Cytometry, Western Blotting, and Immunohistochemistry","volume":"45","author":"Yamamoto","year":"2026","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Shimizu, K., Suzuki, H., Kaneko, M.K., and Kato, Y. (2026). Ca13Mab-17, a Novel Anti-Cadherin-13 Monoclonal Antibody for Versatile Applications. Antibodies, 15.","DOI":"10.20944\/preprints202603.2285.v1"},{"key":"ref_26","first-page":"102138","article-title":"Development of an anti-CDH15\/M-cadherin monoclonal antibody Ca(15)Mab-1 for flow cytometry, immunoblotting, and immunohistochemistry","volume":"43","author":"Ubukata","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"21679436261428408","DOI":"10.1177\/21679436261428408","article-title":"Development of Anti-Human Cadherin-26 Monoclonal Antibody, Ca(26)Mab-6, for Flow Cytometry","volume":"45","author":"Satofuka","year":"2026","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1111\/j.1749-6632.2000.tb05236.x","article-title":"Intestinal cell adhesion molecules. Liver-intestine cadherin","volume":"915","author":"Gessner","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Kohn, K.W., Zeeberg, B.M., Reinhold, W.C., and Pommier, Y. (2014). Gene expression correlations in human cancer cell lines define molecular interaction networks for epithelial phenotype. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0099269"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Ianole, V., Giu\u0219c\u0103, S.E., and C\u0103runtu, I.D. (2025). Evidence for the Prognostic Value of CDH17 Expression in Colorectal Carcinoma. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26146960"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1007\/s00428-005-0015-2","article-title":"Clinicopathological significant and prognostic influence of cadherin-17 expression in gastric cancer","volume":"447","author":"Ito","year":"2005","journal-title":"Virchows Arch."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.bbrc.2004.04.197","article-title":"Overexpression of LI-cadherin in gastric cancer is associated with lymph node metastasis","volume":"319","author":"Ko","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1097\/IGC.0b013e318261d89c","article-title":"Up-regulation of cadherin 17 and down-regulation of homeodomain protein CDX2 correlate with tumor progression and unfavorable prognosis in epithelial ovarian cancer","volume":"22","author":"Huang","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/j.bbrc.2003.10.032","article-title":"Identification of liver-intestine cadherin in hepatocellular carcinoma\u2014A potential disease marker","volume":"311","author":"Wong","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1111\/his.12535","article-title":"Cadherin 17 is frequently expressed by \u2018sclerosing variant\u2019 pancreatic neuroendocrine tumour","volume":"66","author":"Johnson","year":"2015","journal-title":"Histopathology"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1007\/s12015-020-10055-0","article-title":"Chromatin Dynamics in Intestinal Epithelial Homeostasis: A Paradigm of Cell Fate Determination versus Cell Plasticity","volume":"16","author":"Rispal","year":"2020","journal-title":"Stem Cell Rev. Rep."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.bbadis.2010.11.008","article-title":"The role of CDX2 in intestinal homeostasis and inflammation","volume":"1812","author":"Coskun","year":"2011","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0304-3835(01)00753-4","article-title":"Ectopic expression of homeodomain protein CDX2 in intestinal metaplasia and carcinomas of the stomach","volume":"176","author":"Bai","year":"2002","journal-title":"Cancer Lett."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/386084a0","article-title":"Homeosis and intestinal tumours in Cdx2 mutant mice","volume":"386","author":"Chawengsaksophak","year":"1997","journal-title":"Nature"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.clon.2008.01.013","article-title":"A clinicopathological study on the expression of cadherin-17 and caudal-related homeobox transcription factor (CDX2) in human gastric carcinoma","volume":"20","author":"Ge","year":"2008","journal-title":"Clin. Oncol. (R. Coll. Radiol.)"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1007\/s10620-006-9316-9","article-title":"Altered expression of a Li-cadherin in gastric cancer and intestinal metaplasia","volume":"52","author":"Dong","year":"2007","journal-title":"Dig. Dis. Sci."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1111\/j.1440-1827.2006.01946.x","article-title":"Molecular characteristics of differentiated-type gastric carcinoma with distinct mucin phenotype: LI-cadherin is associated with intestinal phenotype","volume":"56","author":"Motoshita","year":"2006","journal-title":"Pathol. Int."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1158\/1078-0432.CCR-17-1444","article-title":"Monoclonal Antibodies Directed against Cadherin RGD Exhibit Therapeutic Activity against Melanoma and Colorectal Cancer Metastasis","volume":"24","author":"Aizpurua","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_44","first-page":"102265","article-title":"Epitope analysis of an anti-mouse CCR1 monoclonal antibody S15040E using flow cytometry","volume":"44","author":"Okada","year":"2025","journal-title":"Biochem. Biophys. Rep."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1158\/1535-7163.MCT-20-0253","article-title":"Selective Tumor Cell Apoptosis and Tumor Regression in CDH17-Positive Colorectal Cancer Models using BI 905711, a Novel Liver-Sparing TRAILR2 Agonist","volume":"20","author":"Wang","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1158\/2767-9764.CRC-25-0638","article-title":"BI 905711, a TRAILR2\/CDH17 Bispecific Antibody, Alone or with Chemotherapy for Patients with Advanced Gastrointestinal Cancers: Phase I Study Findings","volume":"6","author":"Harding","year":"2026","journal-title":"Cancer Res. Commun."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2441411","DOI":"10.1080\/19420862.2024.2441411","article-title":"A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity","volume":"17","author":"Synan","year":"2025","journal-title":"MAbs"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"102213","DOI":"10.1016\/j.xcrm.2025.102213","article-title":"Overcoming multidrug resistance in gastrointestinal cancers with a CDH17-targeted ADC conjugated to a DNA topoisomerase inhibitor","volume":"6","author":"Wang","year":"2025","journal-title":"Cell Rep. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"0041","DOI":"10.34133\/bmr.0041","article-title":"Cadherin 17 Nanobody-Mediated Near-Infrared-II Fluorescence Imaging-Guided Surgery and Immunotoxin Delivery for Colorectal Cancer","volume":"28","author":"Ding","year":"2024","journal-title":"Biomater. Res."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1021\/acs.molpharmaceut.4c01285","article-title":"Development and Characterization of the [(177)Lu]Lu-Labeled Anti-CDH17 Nanobody Derivative for Radioimmunotherapy in the Gastric Cancer Xenograft Model","volume":"22","author":"Mao","year":"2025","journal-title":"Mol. Pharm."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"eadr1928","DOI":"10.1126\/scitranslmed.adr1928","article-title":"Systemic delivery of cadherin 17-specific CAR T cells allows effective and safe targeting of colorectal cancer liver metastases","volume":"17","author":"Greco","year":"2025","journal-title":"Sci. Transl. Med."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/s43018-022-00344-7","article-title":"Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissues","volume":"3","author":"Feng","year":"2022","journal-title":"Nat. Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1016\/j.apsb.2025.03.039","article-title":"CDH17-targeting CAR-NK cells synergize with CD47 blockade for potent suppression of gastrointestinal cancers","volume":"15","author":"Zheng","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13046-026-03693-8","article-title":"Cadherin 17 and digestive cancers: From diagnostic to therapeutic opportunities","volume":"45","author":"Fernandez","year":"2026","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Suzuki, H., Ohishi, T., Tanaka, T., Kaneko, M.K., and Kato, Y. (2024). Anti-HER2 Cancer-Specific mAb, H(2)Mab-250-hG(1), Possesses Higher Complement-Dependent Cytotoxicity than Trastuzumab. Int. J. Mol. Sci., 25.","DOI":"10.20944\/preprints202407.0864.v1"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1089\/mab.2023.0033","article-title":"Establishment of a Novel Cancer-Specific Anti-HER2 Monoclonal Antibody H(2)Mab-250\/H(2)CasMab-2 for Breast Cancers","volume":"43","author":"Kaneko","year":"2024","journal-title":"Monoclon. Antibodies Immunodiagn. Immunother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.stem.2025.05.007","article-title":"Preferential tumor targeting of HER2 by iPSC-derived CAR T cells engineered to overcome multiple barriers to solid tumor efficacy","volume":"32","author":"Hosking","year":"2025","journal-title":"Cell Stem Cell"}],"container-title":["Antibodies"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/59\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T04:19:39Z","timestamp":1783829979000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4468\/15\/4\/59"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,10]]},"references-count":57,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["antib15040059"],"URL":"https:\/\/doi.org\/10.3390\/antib15040059","relation":{},"ISSN":["2073-4468"],"issn-type":[{"value":"2073-4468","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,10]]}}}